Monitoring of skeletal progression of prostate cancer by GFP imaging, X‐ray, and serum OPG and PTHrP
- 23 July 2004
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 62 (3), 275-281
- https://doi.org/10.1002/pros.20146
Abstract
Background Prostate cancers (PCas) produce factors that can serve as biomarkers for tumor metastasis and bone progression. Transduced GFP expression by cancer cells can be imaged to monitor therapy. We exploited both concepts by developing a GFP‐expressing PCa cell line that expresses PTHrP and studying it in an animal model of malignancy with methods that assess the skeletal progression of this tumor. Methods We developed a GFP‐producing PCa cell line by stable transduction of PC‐3 PCa cells. This PC‐3 variant was used to study tumor progression in an immunocompromised mouse model. Skeletal progression of the PCa cells and the effects of pamidronate administration were evaluated radiologically, fluorometrically, and by measurement of serum tumor markers. Results The PC‐3 cells produced extensive bone lesions when injected into the tibia of immunocompromised mice. The skeletal progression of the PC‐3 cells could be monitored by GFP optical imaging, X‐ray, and by measurements of tumor products in serum, notably PTHrP and OPG. Pamidronate treatment reduced tumor burden as assessed at autopsy by imaging and biomarkers. Conclusions Pamidronate treatment exhibited anti‐tumor effects that were reflected by decreases in serum PTHrP, OPG, and by GFP and radiological imaging procedures. Imaging of GFP expression enables real‐time monitoring of tumor growth in the bone. PTHrP and OPG may be useful as tumor biomarkers for PCa that has metastasized to bone. This novel human PCa model can be used to study the clinical potential of diagnostic and therapeutic modalities in the skeletal progression of PCas.Keywords
This publication has 24 references indexed in Scilit:
- Molecular biology of prostate cancerProstate Cancer and Prostatic Diseases, 2004
- Biology of the TRANCE axisCytokine & Growth Factor Reviews, 2003
- Bone markers in the management of patients with skeletal metastasesCancer, 2003
- Osteoprotegerin and rank ligand expression in prostate cancerUrology, 2001
- Prostate carcinomaCancer, 2000
- Metastatic patterns of prostate cancer: An autopsy study of 1,589 patientsHuman Pathology, 2000
- The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone ResorptionJournal of Bone and Mineral Research, 2000
- Characterization of the cell-specific expression of parathyroid hormone–related protein in normal and neoplastic prostate tissueUrology, 1998
- Granin-A, parathyroid hormone-related protein, and calcitonin gene products in neuroendocrine prostate cancerThe Prostate, 1998
- Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.JCI Insight, 1996